Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml
Background Recent studies have suggested that IGF‐I and IGFBP‐3, in combination with PSA, may enhance PCa detection. This study was to investigate the use of serum IGF‐I and IGFBP‐3, and their combinations with prostate volume and fPSA in enhancing the discriminatory diagnosis of PCa in men with tPS...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2007-07, Vol.96 (1), p.54-61 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 61 |
|---|---|
| container_issue | 1 |
| container_start_page | 54 |
| container_title | Journal of surgical oncology |
| container_volume | 96 |
| creator | Zhigang, Zhao Jieming, Liu Su, Li Wenlu, Shen |
| description | Background
Recent studies have suggested that IGF‐I and IGFBP‐3, in combination with PSA, may enhance PCa detection. This study was to investigate the use of serum IGF‐I and IGFBP‐3, and their combinations with prostate volume and fPSA in enhancing the discriminatory diagnosis of PCa in men with tPSA of 4.0–10.0 ng/ml.
Methods
Serum IGF‐I and IGFBP‐3 were determined by ELISA from 586 men with tPSA between 4.0 and 10.0 ng/ml. Of them, 281 were diagnosed with PCa and 305 without. ROC, univariate and multivariate logistic regression analyses were performed to evaluate the predictive performance of those parameters.
Results
IGF‐I, IGFD, IGF‐I/fPSA, and IGFBP‐3/fPSA were significantly higher in PCa cases than benign controls, whereas the differences of IGFBP‐3 and IGFBPD were statistically insignificant between the two groups, respectively. The AUC values indicated enhanced performance of IGF‐I/fPSA ratio (AUC = 0.753) in PCa detection compared with the currently used f/tPSA (AUC = 0.689). Multivariate logistic regression confirmed the observed relationships and identified IGF‐I/fPSA as independent factor in PCa presence.
Conclusion
Our data show that IGF‐I/fPSA as a promising marker can enhance PCa detection in ambiguous cases often found in the tPSA between 4.0 and 10.0 ng/ml. J. Surg. Oncol. 2007;96:54–61. © 2007 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/jso.20784 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70684189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70684189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3614-1ca9b8f3e89901a3640ede46b70475fa4e5fac045eb6c02b61489ccd1af2886c3</originalsourceid><addsrcrecordid>eNp1kc9uEzEQhy0EoqFw4AWQT4geNhnver32sSo0BFW0UkBIuVheZzZ1u39S26u079KHxSWBnrjYsvx9v_F4CHnPYMoA8tlNGKY5VJK_IBMGSmQKlHxJJukuz3il4Ii8CeEGAJQS_DU5YlXBy1IVE_K4RD921PVhbF2fte4W6cYPu3hNG2Pj4Oli1nhEuvVDiCYiDVu0rnGWmj66Dfb002J-niXqanl6Qr2JbqDYX5veYni27NPZ0zVGtInoU0XaJXnnUqU4RNPS5FM-hSx1BbTfzLr2LXnVmDbgu8N-TH6ef_lx9jW7uJwvzk4vMlsIxjNmjaplU6BUCpgpBAdcIxd1BbwqG8MxLRZ4ibWwkNfJkcraNTNNLqWwxTH5uM9Nz70bMUTduWCxbU2Pwxh0BUJyJlUCT_agTX0Fj43eetcZ_6AZ6KdR6DQK_WcUif1wCB3rDtfP5OHvEzDbAzvX4sP_k_S35eXfyGxvuBDx_p9h_K0WVVGV-tf3uV6t2Ge5XK30VfEb7KaiUg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70684189</pqid></control><display><type>article</type><title>Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhigang, Zhao ; Jieming, Liu ; Su, Li ; Wenlu, Shen</creator><creatorcontrib>Zhigang, Zhao ; Jieming, Liu ; Su, Li ; Wenlu, Shen</creatorcontrib><description>Background
Recent studies have suggested that IGF‐I and IGFBP‐3, in combination with PSA, may enhance PCa detection. This study was to investigate the use of serum IGF‐I and IGFBP‐3, and their combinations with prostate volume and fPSA in enhancing the discriminatory diagnosis of PCa in men with tPSA of 4.0–10.0 ng/ml.
Methods
Serum IGF‐I and IGFBP‐3 were determined by ELISA from 586 men with tPSA between 4.0 and 10.0 ng/ml. Of them, 281 were diagnosed with PCa and 305 without. ROC, univariate and multivariate logistic regression analyses were performed to evaluate the predictive performance of those parameters.
Results
IGF‐I, IGFD, IGF‐I/fPSA, and IGFBP‐3/fPSA were significantly higher in PCa cases than benign controls, whereas the differences of IGFBP‐3 and IGFBPD were statistically insignificant between the two groups, respectively. The AUC values indicated enhanced performance of IGF‐I/fPSA ratio (AUC = 0.753) in PCa detection compared with the currently used f/tPSA (AUC = 0.689). Multivariate logistic regression confirmed the observed relationships and identified IGF‐I/fPSA as independent factor in PCa presence.
Conclusion
Our data show that IGF‐I/fPSA as a promising marker can enhance PCa detection in ambiguous cases often found in the tPSA between 4.0 and 10.0 ng/ml. J. Surg. Oncol. 2007;96:54–61. © 2007 Wiley‐Liss, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.20784</identifier><identifier>PMID: 17345593</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; Biomarkers, Tumor - blood ; Humans ; insulin-like growth factor binding protein 3 (IGFBP-3) ; Insulin-Like Growth Factor Binding Protein 3 - blood ; insulin-like growth factor I (IGF-I) ; Insulin-Like Growth Factor I - analysis ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; prostate carcinoma (PCa) ; prostate specific antigen (PSA) ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - diagnosis ; ROC Curve ; Sensitivity and Specificity</subject><ispartof>Journal of surgical oncology, 2007-07, Vol.96 (1), p.54-61</ispartof><rights>Copyright © 2007 Wiley‐Liss, Inc.</rights><rights>Copyright 2007 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3614-1ca9b8f3e89901a3640ede46b70475fa4e5fac045eb6c02b61489ccd1af2886c3</citedby><cites>FETCH-LOGICAL-c3614-1ca9b8f3e89901a3640ede46b70475fa4e5fac045eb6c02b61489ccd1af2886c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.20784$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.20784$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17345593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhigang, Zhao</creatorcontrib><creatorcontrib>Jieming, Liu</creatorcontrib><creatorcontrib>Su, Li</creatorcontrib><creatorcontrib>Wenlu, Shen</creatorcontrib><title>Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
Recent studies have suggested that IGF‐I and IGFBP‐3, in combination with PSA, may enhance PCa detection. This study was to investigate the use of serum IGF‐I and IGFBP‐3, and their combinations with prostate volume and fPSA in enhancing the discriminatory diagnosis of PCa in men with tPSA of 4.0–10.0 ng/ml.
Methods
Serum IGF‐I and IGFBP‐3 were determined by ELISA from 586 men with tPSA between 4.0 and 10.0 ng/ml. Of them, 281 were diagnosed with PCa and 305 without. ROC, univariate and multivariate logistic regression analyses were performed to evaluate the predictive performance of those parameters.
Results
IGF‐I, IGFD, IGF‐I/fPSA, and IGFBP‐3/fPSA were significantly higher in PCa cases than benign controls, whereas the differences of IGFBP‐3 and IGFBPD were statistically insignificant between the two groups, respectively. The AUC values indicated enhanced performance of IGF‐I/fPSA ratio (AUC = 0.753) in PCa detection compared with the currently used f/tPSA (AUC = 0.689). Multivariate logistic regression confirmed the observed relationships and identified IGF‐I/fPSA as independent factor in PCa presence.
Conclusion
Our data show that IGF‐I/fPSA as a promising marker can enhance PCa detection in ambiguous cases often found in the tPSA between 4.0 and 10.0 ng/ml. J. Surg. Oncol. 2007;96:54–61. © 2007 Wiley‐Liss, Inc.</description><subject>Aged</subject><subject>Biomarkers, Tumor - blood</subject><subject>Humans</subject><subject>insulin-like growth factor binding protein 3 (IGFBP-3)</subject><subject>Insulin-Like Growth Factor Binding Protein 3 - blood</subject><subject>insulin-like growth factor I (IGF-I)</subject><subject>Insulin-Like Growth Factor I - analysis</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>prostate carcinoma (PCa)</subject><subject>prostate specific antigen (PSA)</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQhy0EoqFw4AWQT4geNhnver32sSo0BFW0UkBIuVheZzZ1u39S26u079KHxSWBnrjYsvx9v_F4CHnPYMoA8tlNGKY5VJK_IBMGSmQKlHxJJukuz3il4Ii8CeEGAJQS_DU5YlXBy1IVE_K4RD921PVhbF2fte4W6cYPu3hNG2Pj4Oli1nhEuvVDiCYiDVu0rnGWmj66Dfb002J-niXqanl6Qr2JbqDYX5veYni27NPZ0zVGtInoU0XaJXnnUqU4RNPS5FM-hSx1BbTfzLr2LXnVmDbgu8N-TH6ef_lx9jW7uJwvzk4vMlsIxjNmjaplU6BUCpgpBAdcIxd1BbwqG8MxLRZ4ibWwkNfJkcraNTNNLqWwxTH5uM9Nz70bMUTduWCxbU2Pwxh0BUJyJlUCT_agTX0Fj43eetcZ_6AZ6KdR6DQK_WcUif1wCB3rDtfP5OHvEzDbAzvX4sP_k_S35eXfyGxvuBDx_p9h_K0WVVGV-tf3uV6t2Ge5XK30VfEb7KaiUg</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>Zhigang, Zhao</creator><creator>Jieming, Liu</creator><creator>Su, Li</creator><creator>Wenlu, Shen</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070701</creationdate><title>Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml</title><author>Zhigang, Zhao ; Jieming, Liu ; Su, Li ; Wenlu, Shen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3614-1ca9b8f3e89901a3640ede46b70475fa4e5fac045eb6c02b61489ccd1af2886c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor - blood</topic><topic>Humans</topic><topic>insulin-like growth factor binding protein 3 (IGFBP-3)</topic><topic>Insulin-Like Growth Factor Binding Protein 3 - blood</topic><topic>insulin-like growth factor I (IGF-I)</topic><topic>Insulin-Like Growth Factor I - analysis</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>prostate carcinoma (PCa)</topic><topic>prostate specific antigen (PSA)</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhigang, Zhao</creatorcontrib><creatorcontrib>Jieming, Liu</creatorcontrib><creatorcontrib>Su, Li</creatorcontrib><creatorcontrib>Wenlu, Shen</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhigang, Zhao</au><au>Jieming, Liu</au><au>Su, Li</au><au>Wenlu, Shen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>96</volume><issue>1</issue><spage>54</spage><epage>61</epage><pages>54-61</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
Recent studies have suggested that IGF‐I and IGFBP‐3, in combination with PSA, may enhance PCa detection. This study was to investigate the use of serum IGF‐I and IGFBP‐3, and their combinations with prostate volume and fPSA in enhancing the discriminatory diagnosis of PCa in men with tPSA of 4.0–10.0 ng/ml.
Methods
Serum IGF‐I and IGFBP‐3 were determined by ELISA from 586 men with tPSA between 4.0 and 10.0 ng/ml. Of them, 281 were diagnosed with PCa and 305 without. ROC, univariate and multivariate logistic regression analyses were performed to evaluate the predictive performance of those parameters.
Results
IGF‐I, IGFD, IGF‐I/fPSA, and IGFBP‐3/fPSA were significantly higher in PCa cases than benign controls, whereas the differences of IGFBP‐3 and IGFBPD were statistically insignificant between the two groups, respectively. The AUC values indicated enhanced performance of IGF‐I/fPSA ratio (AUC = 0.753) in PCa detection compared with the currently used f/tPSA (AUC = 0.689). Multivariate logistic regression confirmed the observed relationships and identified IGF‐I/fPSA as independent factor in PCa presence.
Conclusion
Our data show that IGF‐I/fPSA as a promising marker can enhance PCa detection in ambiguous cases often found in the tPSA between 4.0 and 10.0 ng/ml. J. Surg. Oncol. 2007;96:54–61. © 2007 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17345593</pmid><doi>10.1002/jso.20784</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2007-07, Vol.96 (1), p.54-61 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70684189 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Biomarkers, Tumor - blood Humans insulin-like growth factor binding protein 3 (IGFBP-3) Insulin-Like Growth Factor Binding Protein 3 - blood insulin-like growth factor I (IGF-I) Insulin-Like Growth Factor I - analysis Logistic Models Male Middle Aged Multivariate Analysis prostate carcinoma (PCa) prostate specific antigen (PSA) Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnosis ROC Curve Sensitivity and Specificity |
| title | Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A51%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20insulin-like%20growth%20factor%20I/free%20prostate%20specific%20antigen%20(IGF-I/fPSA)%20ratio%20enhances%20prostate%20cancer%20detection%20in%20men%20with%20total%20PSA%204.0-10.0%20ng/ml&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Zhigang,%20Zhao&rft.date=2007-07-01&rft.volume=96&rft.issue=1&rft.spage=54&rft.epage=61&rft.pages=54-61&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.20784&rft_dat=%3Cproquest_cross%3E70684189%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70684189&rft_id=info:pmid/17345593&rfr_iscdi=true |